Source comparison
Tesamorelin + Ipamorelin Blend: Mechanism Comparison
Tesamorelin GHRH receptor agonist. Binds anterior pituitary receptors to stimulate sustained GH secretion 26–38 minutes (plasma); GH elevation persists 3–6 hours ~9 minutes (Cmax) 3–6 hours sustained elevation Ideal for maintaining baseline GH elevation; resis
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH receptor agonist. Binds anterior pituitary receptors to stimulate sustained GH secretion
- 26–38 minutes (plasma); GH elevation persists 3–6 hours
- ~9 minutes (Cmax)
- 3–6 hours sustained elevation
- Ideal for maintaining baseline GH elevation; resists DPP-4 degradation due to lipophilic modification
- Ipamorelin
- Ghrelin receptor agonist (GHS-R1a). Triggers pulsatile GH release without cortisol/prolactin elevation
- ~2 hours (peptide clearance); GH pulse resolves within 3 hours
- 30–60 minutes
- 1–3 hours (pulsatile)
- Produces acute GH surge mimicking natural nocturnal pulse; highly selective with minimal off-target effects
- Blended Protocol
- Dual-phase: ipamorelin initiates acute pulse, tesamorelin sustains baseline
- Overlapping (sequential peaks)
- Dual peaks: 30–60 min + sustained 3–6 hours
- 4–8 hours total GH exposure
- Synergistic AUC only achieved when co-administered within same dosing window; separation by >60 min eliminates benefit